<DOC>
	<DOC>NCT01288157</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetics of golimumab in Chinese male participants.</brief_summary>
	<brief_title>A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects</brief_title>
	<detailed_description>This is a randomized (study medication assigned by chance), open-label (both the physician and subject know the assigned study medication) study to assess the safety, tolerability, immune response, pharmacokinetics (what the body does to the drug), of golimumab (Simponi). The study population will consist of 24 healthy male participants in China. Subjects will receive a single dose of either 50 mg or 100 mg golimumab. Subjects will be in the study for up to 14 weeks. Safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (eg, blood pressure), and the occurrence and severity of adverse events. A single dose of 50 mg or 100 mg golimumab as a subcutaneous injection.</detailed_description>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Have no clinically relevant abnormalities nonsmoker or agree to smoke no more than 10 cigarettes or 2 cigars per day throughout the study. Have or had a history of clinically significant, severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease Have any underlying physical or psychological medical condition Be unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>healthy</keyword>
	<keyword>adult</keyword>
	<keyword>Chinese</keyword>
	<keyword>male</keyword>
	<keyword>Simponi</keyword>
	<keyword>CNTO 148</keyword>
</DOC>